Phase 1 Clinical Trial Tests Dengue Secondary Infection Dynamics
A controlled human challenge study involving 45 healthy adults has revealed how preexisting immunity shapes viral replication and immune responses during secondary dengue virus infections. Published in Science Translational Medicine, the research clarifies why secondary infections with dengue are frequently more severe than primary exposures, a major hurdle in vaccine development.
Camila Odio and colleagues at the American Association for the Advancement of Science reported that participants received injections of a live, weakened strain of DENV3. The trial evaluated volunteers with zero, one, or multiple prior infections across the four dengue strains, DENV1 through DENV4. Secondary infections produced greater viremia, higher neutralizing antibody counts, and stronger T cell responses compared to primary or tertiary infections, alongside mild clinical symptoms.
Immune Mechanisms Drive Viral Replication Contrasts
The trial isolated distinct immune trajectories depending on baseline antibody profiles. Volunteers whose baseline antibodies enhanced viral replication in an in vitro assay experienced the highest viral counts, delayed inflammatory and adaptive immune activation, and a subsequent waning of CD8+ T cells and antibodies.
Conversely, participants who carried higher levels of antibodies against the viral nonstructural protein 1 across multiple serotypes displayed early interferon production and balanced immune activation. This profile successfully controlled viremia and fostered enduring, potent B and T cells. Individuals possessing potent neutralizing antibodies and IFN-γ+ T cells at baseline showed minimal viral replication overall.
Frequently Asked Questions About the Dengue Challenge Study
How many participants were enrolled in the Phase 1 trial?
The clinical trial enrolled 45 healthy adult volunteers with varying histories of prior dengue virus exposure.
What specific dengue strain was administered to the volunteers?
Researchers administered a live, weakened strain of the DENV3 virus to challenge the participants in a controlled setting.
What did higher antibodies against nonstructural protein 1 predict?
Higher baseline antibodies against nonstructural protein 1 across multiple serotypes predicted early interferon activity, balanced immune activation, viral replication control, and the development of enduring B and T cells.
Keep reading